Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clustoid MM09 placebo-controlled trial in house dust mite allergic rhinitis/rhinoconjunctivitis with or without mild to moderate asthma
2024-514090-21-00Phase 3Completed
- Sponsor
- Inmunotek
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma comparing Clustoid MM09 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Aug 2024; status: completed.
02
Drugs
Clustoid MM09
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2024-514090-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514090-21-00.